180 related articles for article (PubMed ID: 9735417)
1. Biomarkers in Barrett's esophagus (review).
van Lieshout EM; Jansen JB; Peters WH
Int J Oncol; 1998 Oct; 13(4):855-64. PubMed ID: 9735417
[TBL] [Abstract][Full Text] [Related]
2. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
3. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
4. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
5. Is Barrett's esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study.
Mendes de Almeida JC; Chaves P; Pereira AD; Altorki NK
Ann Surg; 1997 Dec; 226(6):725-33; discussion 733-5. PubMed ID: 9409571
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
7. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
8. Acidic fibroblast growth factor is expressed sequentially in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Soslow RA; Petersen CG; Remotti H; Altorki N
Dis Esophagus; 2001; 14(1):23-7. PubMed ID: 11422301
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
10. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
11. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett's esophagus and esophageal adenocarcinoma.
Ozcan HEA; Anuk T; Ozden O
Adv Med Sci; 2018 Sep; 63(2):296-300. PubMed ID: 29803118
[TBL] [Abstract][Full Text] [Related]
12. Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.
Iannettoni MD; Lee SS; Bonnell MR; Sell TL; Whyte RI; Orringer MB; Beer DG
Ann Thorac Surg; 1996 Nov; 62(5):1460-5; discussion 1465-6. PubMed ID: 8893584
[TBL] [Abstract][Full Text] [Related]
13. Barrett's esophagus and esophageal adenocarcinoma.
Reid BJ
Gastroenterol Clin North Am; 1991 Dec; 20(4):817-34. PubMed ID: 1787015
[TBL] [Abstract][Full Text] [Related]
14. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
15. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
[TBL] [Abstract][Full Text] [Related]
16. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma.
Soslow RA; Ying L; Altorki NK
J Thorac Cardiovasc Surg; 1997 Nov; 114(5):838-43. PubMed ID: 9375615
[TBL] [Abstract][Full Text] [Related]
17. Progression to cancer in Barrett's esophagus is associated with genomic instability.
Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE
Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effects of non-steroidal anti-inflammatory drugs in Barrett's oesophagus.
Rajendra S
Lancet Oncol; 2006 Feb; 7(2):103-4. PubMed ID: 16455473
[No Abstract] [Full Text] [Related]
19. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
20. How Should We Report Endoscopic Results in Patient's with Barrett's Esophagus?
Gorrepati VS; Sharma P
Dig Dis Sci; 2018 Aug; 63(8):2115-2121. PubMed ID: 29675664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
